Analysis for TRV
$383.89
+6.07
(+1.61%)
- 📈 Growth — 26/30
- 💰 Profitability — 18/20
- 🏦 Financial Health — 15/20
- 💵 Valuation — 12/20
- ⚠️ Risk — 5/10
Overall Score: 76/100
Summary:
📈 Growth & Financial Trajectory
Over the 8 quarters, Revenue rose from about $11.90B in 2024 Q3 to $12.15B in 2026 Q2 (~2% growth). Net income climbed from ~$1.27B to ~$2.21B, up ~74%, signaling improving profitability despite modest top-line growth. The cadence shows steady earnings leverage with a meaningful step-up in late 2025.
💰 Margins & Cash Flow
- Operating Margin ranged mid-teens to about 25% (peak in 2025 Q4:
25%), reflecting strong margin mix. - Cash Flow From Operating Activities (continuing) largely positive across quarters (roughly $1.9–$2.7B in several periods; 2026 Q2: $1.92B). - Net Cash Flow was modestly positive or near break-even in later quarters as investing outflows ($1.7–$3.4B) and financing moves offset operating cash.
🛡️ Balance Sheet & Liquidity
Current assets ~$143.58B vs current liabilities ~$110.46B yields a Current Ratio ~1.30x. Equity ≈ $33.12B with virtually no noncurrent liabilities evident, and total assets ~$143.58B, indicating solid liquidity and asset support for near-term obligations.
⚠️ Key Drivers & Risks
- Drivers: underwriting profitability and premium revenue; strong investment income support.
- Risks: catastrophe/claims volatility, sensitivity to interest rates, and concentration in short-dated liabilities could pressure liquidity if rates or claims sharpen.
📊 Key Financial Fundamentals
Valuation Multiples
Market Cap
$78.84B
P/E Ratio
9.50
Forward P/E
11.83
P/S Ratio
1.61
P/B Ratio
2.08
EV / EBITDA
7.60
Profitability & Returns
Gross Margin
N/A
Operating Margin
22.02%
Net Margin
16.95%
ROE
25.62%
ROIC
19.95%
Financial Health & Liquidity
Current Ratio
1.00
Quick Ratio
1.00
Financial Scale & Cash Flow
Revenue
$48.99B
Net Income
$8.30B
FCF Yield
13.99%
Free Cash Flow
$11.03B
Total Debt To Equity
0.27